TY - JOUR
T1 - Updating the OMERACT filter
T2 - implications for imaging and soluble biomarkers
AU - D'Agostino, Maria-Antonietta
AU - Boers, Maarten
AU - Kirwan, John
AU - van der Heijde, Désirée
AU - Østergaard, Mikkel
AU - Schett, Georg
AU - Landewé, Robert B
AU - Maksymowych, Walter P
AU - Naredo, Esperanza
AU - Dougados, Maxime
AU - Iagnocco, Annamaria
AU - Bingham, Clifton O
AU - Brooks, Peter M
AU - Beaton, Dorcas E
AU - Gandjbakhch, Frederique
AU - Gossec, Laure
AU - Guillemin, Francis
AU - Hewlett, Sarah E
AU - Kloppenburg, Margreet
AU - March, Lyn
AU - Mease, Philip J
AU - Moller, Ingrid
AU - Simon, Lee S
AU - Singh, Jasvinder A
AU - Strand, Vibeke
AU - Wakefield, Richard J
AU - Wells, George A
AU - Tugwell, Peter
AU - Conaghan, Philip G
PY - 2014/5
Y1 - 2014/5
N2 - OBJECTIVE: The Outcome Measures in Rheumatology (OMERACT) Filter provides a framework for the validation of outcome measures for use in rheumatology clinical research. However, imaging and biochemical measures may face additional validation challenges because of their technical nature. The Imaging and Soluble Biomarker Session at OMERACT 11 aimed to provide a guide for the iterative development of an imaging or biochemical measurement instrument so it can be used in therapeutic assessment.METHODS: A hierarchical structure was proposed, reflecting 3 dimensions needed for validating an imaging or biochemical measurement instrument: outcome domain(s), study setting, and performance of the instrument. Movement along the axes in any dimension reflects increasing validation. For a given test instrument, the 3-axis structure assesses the extent to which the instrument is a validated measure for the chosen domain, whether it assesses a patient-centered or disease-centered variable, and whether its technical performance is adequate in the context of its application. Some currently used imaging and soluble biomarkers for rheumatoid arthritis, spondyloarthritis, and knee osteoarthritis were then evaluated using the original OMERACT Filter and the newly proposed structure. Breakout groups critically reviewed the extent to which the candidate biomarkers complied with the proposed stepwise approach, as a way of examining the utility of the proposed 3-dimensional structure.RESULTS: Although there was a broad acceptance of the value of the proposed structure in general, some areas for improvement were suggested including clarification of criteria for achieving a certain level of validation and how to deal with extension of the structure to areas beyond clinical trials.CONCLUSION: General support was obtained for a proposed tri-axis structure to assess validation of imaging and soluble biomarkers; nevertheless, additional work is required to better evaluate its place within the OMERACT Filter 2.0.
AB - OBJECTIVE: The Outcome Measures in Rheumatology (OMERACT) Filter provides a framework for the validation of outcome measures for use in rheumatology clinical research. However, imaging and biochemical measures may face additional validation challenges because of their technical nature. The Imaging and Soluble Biomarker Session at OMERACT 11 aimed to provide a guide for the iterative development of an imaging or biochemical measurement instrument so it can be used in therapeutic assessment.METHODS: A hierarchical structure was proposed, reflecting 3 dimensions needed for validating an imaging or biochemical measurement instrument: outcome domain(s), study setting, and performance of the instrument. Movement along the axes in any dimension reflects increasing validation. For a given test instrument, the 3-axis structure assesses the extent to which the instrument is a validated measure for the chosen domain, whether it assesses a patient-centered or disease-centered variable, and whether its technical performance is adequate in the context of its application. Some currently used imaging and soluble biomarkers for rheumatoid arthritis, spondyloarthritis, and knee osteoarthritis were then evaluated using the original OMERACT Filter and the newly proposed structure. Breakout groups critically reviewed the extent to which the candidate biomarkers complied with the proposed stepwise approach, as a way of examining the utility of the proposed 3-dimensional structure.RESULTS: Although there was a broad acceptance of the value of the proposed structure in general, some areas for improvement were suggested including clarification of criteria for achieving a certain level of validation and how to deal with extension of the structure to areas beyond clinical trials.CONCLUSION: General support was obtained for a proposed tri-axis structure to assess validation of imaging and soluble biomarkers; nevertheless, additional work is required to better evaluate its place within the OMERACT Filter 2.0.
U2 - 10.3899/jrheum.131313
DO - 10.3899/jrheum.131313
M3 - Journal article
C2 - 24584916
SN - 0315-162X
VL - 41
SP - 1016
EP - 1024
JO - Journal of Rheumatology
JF - Journal of Rheumatology
IS - 5
ER -